{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:42:41Z","timestamp":1792658561047,"version":"4.5.0"},"reference-count":43,"publisher":"Japanese Circulation Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2019,2,25]]},"DOI":"10.1253\/circj.cj-18-0975","type":"journal-article","created":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T17:33:26Z","timestamp":1548351206000},"page":"540-547","source":"Crossref","is-referenced-by-count":10,"title":["Poor Quality of Warfarin Treatment Increases the Risk of All Types of Intracranial Hemorrhage in Atrial Fibrillation"],"prefix":"10.1253","volume":"83","author":[{"given":"Paula","family":"Tiili","sequence":"first","affiliation":[{"name":"Department of Cardiology, Heart and Lung Center, Helsinki University Hospital, University of Helsinki"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jukka","family":"Putaala","sequence":"additional","affiliation":[{"name":"Department of Neurology, Helsinki University Hospital, University of Helsinki"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juha","family":"Meht\u00e4l\u00e4","sequence":"additional","affiliation":[{"name":"EPID Research Oy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houssem","family":"Khanfir","sequence":"additional","affiliation":[{"name":"EPID Research Oy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jussi","family":"Niiranen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Heart and Lung Center, Helsinki University Hospital, University of Helsinki"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasi","family":"Korhonen","sequence":"additional","affiliation":[{"name":"EPID Research Oy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pekka","family":"Raatikainen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Heart and Lung Center, Helsinki University Hospital, University of Helsinki"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Lehto","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Heart and Lung Center, Helsinki University Hospital, University of Helsinki"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>Eur Heart J<\/i> 2016; 37: 2893\u20132962.","DOI":"10.1093\/eurheartj\/ehw210"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: Executive summary: A report of the American College of Cardiology\/American Heart Association task force on practice guidelines and the Heart Rhythm Society. <i>Circulation<\/i> 2014; 130: 2071\u20132104.","DOI":"10.1161\/CIR.0000000000000040"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Veltkamp R, Rizos T, Horstmann S. Intracerebral bleeding in patients on antithrombotic agents. <i>Semin Thromb Hemost<\/i> 2013; 39: 963\u2013971.","DOI":"10.1055\/s-0033-1357506"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy. <i>Stroke<\/i> 2005; 36: 1588\u20131593.","DOI":"10.1161\/01.STR.0000170642.39876.f2"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Friberg L, Rosenqvist M, Lip GYH. Net clinical benefit of warfarin in patients with atrial fibrillation: A report From the Swedish Atrial Fibrillation Cohort Study. <i>Circulation<\/i> 2012; 125: 2298\u20132307.","DOI":"10.1161\/CIRCULATIONAHA.111.055079"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Lip GYH, Skj\u00f8th F, Nielsen PB, Larsen TB. Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score: A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. <i>Thromb Haemost<\/i> 2015; 114: 826\u2013834.","DOI":"10.1160\/TH15-07-0565"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Grysiewicz R, Gorelick PB. Incidence, mortality, and risk factors for oral anticoagulant-associated intracranial hemorrhage in patients with atrial fibrillation. <i>J Stroke Cerebrovasc Dis<\/i> 2014; 23: 2479\u20132488.","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.06.031"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Fang MC, Go AS, Chang Y, Hylek EM, Henault LE, Jensvold NG, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. <i>Am J Med<\/i> 2007; 120: 700\u2013705.","DOI":"10.1016\/j.amjmed.2006.07.034"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Lopes RD, Guimaraes PO, Kolls BJ, Wojdyla DM, Bushnell CD, Hanna M, et al. Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. <i>Blood<\/i> 2017; 129: 2980\u20132987.","DOI":"10.1182\/blood-2016-08-731638"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hart RG, Diener H, Yang S, Connolly SJ, Wallentin L, Reilly PA, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: The RE-LY trial. <i>Stroke<\/i> 2012; 43: 1511\u20131517.","DOI":"10.1161\/STROKEAHA.112.650614"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Witt DM, Delate T, Hylek EM, Clark NP, Crowther MA, Dentali F, et al. Effect of warfarin on intracranial hemorrhage incidence and fatal outcomes. <i>Thromb Res<\/i> 2013; 132: 770\u2013775.","DOI":"10.1016\/j.thromres.2013.10.024"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Giugliano RP, Ruff CT, Rost NS, Silverman S, Wiviott SD, Lowe C, et al. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective anticoagulation with factor xa next generation in atrial fibrillation-thrombolysis in myocardial infarction 48. <i>Stroke<\/i> 2014; 45: 2372\u20132378.","DOI":"10.1161\/STROKEAHA.114.006025"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Franko J, Kish KJ, O\u2019Connell BG, Subramanian S, Yuschak JV. Advanced age and preinjury warfarin anticoagulation increase the risk of mortality after head trauma. <i>J Trauma Inj Infect Crit Care<\/i> 2006; 61: 107\u2013110.","DOI":"10.1097\/01.ta.0000224220.89528.fc"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Gage BF, Birman-Deych E, Kerzner R, Radford MJ, Nilasena DS, Rich MW. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. <i>Am J Med<\/i> 2005; 118: 612\u2013617.","DOI":"10.1016\/j.amjmed.2005.02.022"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Inui TS, Parina R, Chang DC, Inui TS, Coimbra R. Mortality after ground-level fall in the elderly patient taking oral anticoagulation for atrial fibrillation\/flutter: A long-term analysis of risk versus benefit. <i>J Trauma Acute Care Surg<\/i> 2014; 76: 642\u2013649.","DOI":"10.1097\/TA.0000000000000138"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Huhtakangas J, Tetri S, Juvela S, Saloheimo P, Bode MK, Karttunen V, et al. Effect of increased warfarin use on warfarin-related cerebral hemorrhage: A longitudinal population-based Study. <i>Int J Stroke<\/i> 2015; 10: 876\u2013881.","DOI":"10.1111\/j.1747-4949.2012.00926.x"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Hylek EM. Vitamin K antagonists and time in the therapeutic range: Implications, challenges, and strategies for improvement. <i>J Thromb Thrombolysis<\/i> 2013; 35: 333\u2013335.","DOI":"10.1007\/s11239-013-0900-5"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Nieuwlaat R, Connolly BJ, Hubers LM, Cuddy SM, Eikelboom JW, Yusuf S, et al. Quality of individual INR control and the risk of stroke and bleeding events in atrial fibrillation patients: A nested case control analysis of the ACTIVE W study. <i>Thromb Res<\/i> 2012; 129: 715\u2013719.","DOI":"10.1016\/j.thromres.2011.08.024"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Barta AL, Nutescu EA, Thompson PA, Bussey HI, Gulseth MP. Relationship between time spent at extreme international normalized ratios and time in therapeutic range with bleeding and thrombosis in warfarin-treated patients. <i>Am J Health Syst Pharm<\/i> 2015; 72: 1188\u20131194.","DOI":"10.2146\/ajhp140752"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Fang MC, Chang Y, Hylek EM, Rosand J, Greenberg SM, Go AS, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. <i>Ann Intern Med<\/i> 2004; 141: 745\u2013752.","DOI":"10.7326\/0003-4819-141-10-200411160-00005"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: A systematic review. <i>Circ Cardiovasc Qual Outcomes<\/i> 2008; 1: 84\u201391.","DOI":"10.1161\/CIRCOUTCOMES.108.796185"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Lind M, Fahlen M, Kosiborod M, Eliasson B, Oden A. Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation. <i>Thromb Res<\/i> 2012; 129: 32\u201335.","DOI":"10.1016\/j.thromres.2011.07.004"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Van Den Ham HA, Klungel OH, Leufkens HGM, Van Staa TP. The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non-valvular atrial fibrillation. <i>J Thromb Haemost<\/i> 2013; 11: 107\u2013115.","DOI":"10.1111\/jth.12041"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Cancino RS, Hylek EM, Reisman JI, Rose AJ. Comparing patient-level and site-level anticoagulation control as predictors of adverse events. <i>Thromb Res<\/i> 2014; 133: 652\u2013656.","DOI":"10.1016\/j.thromres.2014.01.013"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Amin A, Deitelzweig S, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, et al. Estimation of the impact of warfarin\u2019s time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use: Learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials. <i>J Thromb Thrombolysis<\/i> 2014; 38: 150\u2013159.","DOI":"10.1007\/s11239-013-1048-z"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Ho C, Ho M, Chan P, Hai JJ, Cheung E, Yeung CY, et al. Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: Impact of quality of anticoagulation control. <i>Stroke<\/i> 2015; 46: 23\u201330.","DOI":"10.1161\/STROKEAHA.114.006476"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Bj\u00f6rck F, Renlund H, Lip GYH, Wester P, Svensson PJ, Sj\u00e4lander A. Outcomes in a warfarin-treated population with atrial fibrillation. <i>JAMA Cardiol<\/i> 2016; 1: 172\u2013180.","DOI":"10.1001\/jamacardio.2016.0199"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Lehto M, Niiranen J, Korhonen P, Meht\u00e4l\u00e4 J, Khanfir H, Hoti F, et al. Quality of warfarin therapy and risk of stroke, bleeding, and mortality among patients with atrial fibrillation: Results from the nationwide FinWAF registry. <i>Pharmacoepidemiol Drug Saf<\/i> 2017; 26: 657\u2013665.","DOI":"10.1002\/pds.4194"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. <i>Thromb Haemost<\/i> 1993; 69: 236\u2013239.","DOI":"10.1055\/s-0038-1651587"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. <i>Ann Intern Med<\/i> 2009; 150: 604\u2013612.","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Nelson WW, Wang L, Baser O, Damaraju CV, Schein JR. Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation. <i>Int J Clin Pharm<\/i> 2015; 37: 53\u201359.","DOI":"10.1007\/s11096-014-0038-3"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Mearns ES, White CM, Kohn CG, Hawthorne J, Song JS, Meng J, et al. Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: A meta-analysis and meta-regression. <i>Thromb J<\/i> 2014; 12: 14.","DOI":"10.1186\/1477-9560-12-14"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Hirano T, Kaneko H, Mishina S, Wang F, Morita S. Suboptimal anticoagulant management in Japanese patients with nonvalvular atrial fibrillation receiving warfarin for stroke prevention. <i>J Stroke Cerebrovasc Dis<\/i> 2017; 26: 2102\u20132110.","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.04.030"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. JCS Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013): Digest version. <i>Circ J<\/i> 2014; 78: 1997\u20132021.","DOI":"10.1253\/circj.CJ-66-0092"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Liu T, Hui J, Hou YY, Zou Y, Jiang WP, Yang XJ, et al. Meta-analysis of efficacy and safety of low-intensity warfarin therapy for East Asian patients with nonvalvular atrial fibrillation. <i>Am J Cardiol<\/i> 2017; 120: 1562\u20131567.","DOI":"10.1016\/j.amjcard.2017.07.050"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Sj\u00f6gren V, Grzymala-Lubanski B, Renlund H, Friberg L, Lip GYH, Svensson PJ, et al. Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula. <i>Thromb Haemost<\/i> 2015; 113: 1370\u20131377.","DOI":"10.1160\/TH14-10-0859"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Steiner T, Rosand J, Diringer M. Intracerebral hemorrhage associated with oral anticoagulant therapy: Current practices and unresolved questions. <i>Stroke<\/i> 2006; 37: 256\u2013262.","DOI":"10.1161\/01.STR.0000196989.09900.f8"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Parikh NS, Navi BB, Schneider Y, Jesudian A, Kamel H. Association between cirrhosis and stroke in a nationally representative cohort. <i>JAMA Neurol<\/i> 2017; 74: 927\u2013932.","DOI":"10.1001\/jamaneurol.2017.0923"},{"key":"39","unstructured":"39. Jairath V, Burroughs AK. Anticoagulation in patients with liver cirrhosis: Complication or therapeutic opportunity? <i>Gut<\/i> 2013; 62: 479\u2013482."},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. O\u2019Donnell MJ, Chin SL, Rangarajan S, Xavier D, Liu L, Zhang H, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): A case-control study. <i>Lancet<\/i> 2016; 388: 761\u2013775.","DOI":"10.1016\/S0140-6736(16)30506-2"},{"key":"41","doi-asserted-by":"crossref","unstructured":"42. Eisenstaedt R, Penninx BWJH, Woodman RC. Anemia in the elderly: Current understanding and emerging concepts. <i>Blood Rev<\/i> 2006; 20: 213\u2013226.","DOI":"10.1016\/j.blre.2005.12.002"},{"key":"42","doi-asserted-by":"crossref","unstructured":"43. Westenbrink BD, Alings M, Granger CB, Alexander JH, Lopes R, Hylek EM, et al. Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. <i>Am Heart J<\/i> 2017; 185: 140\u2013149.","DOI":"10.1016\/j.ahj.2016.12.008"},{"key":"43","doi-asserted-by":"crossref","unstructured":"44. Westenbrink BD, Alings M, Connolly SJ, Eikelboom J, Ezekowitz MD, Oldgren J, et al. Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: Insights from the RE-LY trial. <i>J Thromb Haemost<\/i> 2015; 13: 699\u2013707.","DOI":"10.1111\/jth.12874"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/83\/3\/83_CJ-18-0975\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T00:52:28Z","timestamp":1573779148000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/83\/3\/83_CJ-18-0975\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,25]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-18-0975","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,25]]}}}